Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-07-12
2009-06-23
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C560S019000
Reexamination Certificate
active
07550506
ABSTRACT:
The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4962885 (1990-10-01), Coffee
patent: 5112598 (1992-05-01), Biesalski
patent: 5556611 (1996-09-01), Biesalski
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), Van Der Linden et al.
patent: 6254853 (2001-07-01), Hendler et al.
patent: 6362234 (2002-03-01), Hendler
patent: 7220875 (2007-05-01), Gallop et al.
patent: 2001/0025035 (2001-09-01), Stella et al.
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 95/26234 (1995-10-01), None
patent: WO 95/26235 (1995-10-01), None
patent: WO 95/32807 (1995-12-01), None
patent: WO 99/58555 (1999-11-01), None
patent: WO 00/48572 (2000-08-01), None
patent: WO 00/54588 (2000-09-01), None
patent: WO 01/20331 (2001-03-01), None
patent: WO 02/13810 (2002-02-01), None
patent: WO 2004/033424 (2004-04-01), None
patent: WO 2005/021024 (2005-03-01), None
King, Med Chem: Principle and Practice (1994), p. 206-209.
Adibi, “The oligopeptide transporter (Pept-1) in Human Intestine: Biology and Function,”Gastroenterology1997, 113, 332-340.
Alderman, “A Review of cellulose Ethers in Hydrophilic Matrices dor Oral controlled-Release Dosage Forms,”Int. J. Pharm. Tech.&Prod. Mfr. 1984, 5(3) 1-9.
Anderson et al., “Alpha-amino acid phenolic ester derivatives: novel water-soluble general anesthetic agents which allosterically modulate GABA(A) receptors,”J. Med. Chem. 2001, 44, 3582-3591.
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations,”Int. J. Pharm. 1979, 2, 307.
Banaszczyk et al., “Propofol Phosphate, a Water-Soluble Propofol Prodrug: In Vivo Evaluation,”Anesth. Analg. 2002, 95, 1285-1292.
Borgeat et al., “Preliminary Communication: Adjuvant Propofol Enables Better Control of Nausea and Emesid Secondary to Chemotherapy for Breast Cancer,”Can. J. Anaesth. 1994, 41, 1117-1119.
Borgeat et al., “Propofol improves patient comfort during cisplatin chemotherapy. A pilot study,”Oncology1993, 50, 456-459.
Briggs et al., “An Adverse Rection to the Administration of Disoprofol (Diprvan),”Anaesthesia1982, 37, 1099-1101.
Brooker et al., “Propofol Maintence to Reduce Postoperatiove Emesis in Thyroidectomy Patients: A Group Sequential Comparison with Isoflurance/Nitrous Oxide,”Anaesth. Intensive Care1998, 26, 625-629.
Brown et al., “Role of Propofol in Refractory Status Epilepticus,”Pharmacother. 1998, 32, 1053-1059.
De la Cruz et al., “The Effect of Propofol on Oxidative Stress in Platelets from Surgical Patients,”Anesth. Analg. 1999, 89, 1050-1055.
During et al., “Controlled release of dopamine from a polymeric brain implant: in vivo characterization,” 1989,Ann. Neurol. 25:351.
Fieser et al., “Reagents for Organic Synthesis,” vol. 1-17, Wiley Interscience, 2004.
Finch “Theilheimer's Synthetic Methods of Organic Chemistry,” vol. 45, 1991.
Gan et al., “Determination of Plasma Concentrations of Propofol Associated with 50% Reduction in Postoperative Nausea,”Anesthesiology, 1997, 87, 779-784.
Gennaro, “Remington's Pharmaceutical Sciences,” Philadelphia College of Pharmacy and Science, 19th Edition, 1995.
Greene et al.Protective groups in Organic Chemistry, Wiley, 2nded., 1991.
Harrison et al., “Compendium of Synthetic Organic Methods”, vols. 1-8, John Wiley and Sons, 1971-1996.
Hasan et al., “Comparison of the Effects of the Propofol and Thiopental on the Pattern of Maximal Electroshock Seizures in a Rat,”Pharmacol. Toxicol. 1994, 74, 50-53.
Hashimoto et al:, “Abnormal Activity in the Globus Pallidus in the Off-Period Dystonia,”Annals. of Neurology, 2001, 49, 242-275.
Holtkamp et al., “Propofol in subanesthetic doses terminates status epilepticus in a rodent model,”Ann. Neurol. 2001, 49, 260-263.
Howard et al., “Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,” 1989,J. Neurosurg. 71:105-112.
Krusz et al., “Intravenous Propofol: Unique Effectiveness in Treating Intractable Migraine,”Headache2000, 40, 224-230.
Kuisma et al., “Propofol in Prewhospital Treatment of Convulsive Status Epilepticus,”Epilepsia1995, 36, 1241-1243.
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Relaease of Bioactive Agents: A Review,”J Macromol. Sci. Rev. Macromol Chem. 1983, 23:61.
Langer et al., “Medical Applications of Controlled Release,” Langer and Wise (cds), CRC Pres., 1984.
Langley et al., “Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic,”Drugs1988, 35, 334-372.
Larock “Comprehensive Organic Transformations,” VCH Publishers, 1989.
Leibach et al., “Peptide transporters in the intestine and the kidney,”Ann. Rev. Nutr. 1996, 16, 99-119.
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,”Science1985 228: 190-192.
Luckenbach, “Beilstein: Handbook of Organic Chemistry,” Springer-Verlang, Frankfurt, Germany, vol. 25, Part 18, 1993.
March, “Advanced Organic Chemistry,” Wiley Interscience, 1992.
Murphy et al., “The Antioxideant Potential of Propofol (2,6-Diisopropylphenol),”Br. J. Anaesth. 1992, 68, 613-618.
Paquette, “Encyclopedia of Reagents for Organic Synthesis,” John Wiley & Sons, 1995.
Peduto et al., “Biochemical and Electrophysiologic Evidence that Propofol Enhances GABAergic Transmission in the Rat Brain,”Anesthesiology1991, 75, 1000-1009.
Phelps, et al., “Propofol in Chemotherapy-Associated Nausea and Vomiting,”Ann Pharmacother, 1996, 30(3):290-292.
Picard, et al., “Prevention of Pain on Injection with Propofol: A Quantitative Systematic Review,”Anesth. Analg., 2000, 90:963-969.
Pop, et al., “Synthese and Preliminary Pharmacological Evaluation of Some Chemical Delivery Systems of 2,6-diisopropylphenol (Propofol),”Med. Chem. Res., 1992, 2(1):16-21.
Raleigh et al., “Searching for the Link Between Hypoxia and Poor Prognoses in Human Tumors,”Proc. Amer. Assoc. Cancer Research Annual Meeting, 1999, 40, 397.
Raleigh et al., “Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation,”British. J. Cancer, 1999, 80, Suppl. 2, 96-97.
Raoof, et al., “In Vivo Assessment of Intestinal, Hepatic, and Pulmonary First Pass Metobolism of Propofol in the Rat,”Pharm Res, 1996, 13(6):891-895.
Sagara, et al., “Propofol Hemisuccinate Protects Neuronal Cells from Oxidative Injury,”J. Neurochem., 1999, 73(6):2524-2530.
Saudek et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,”N. Engl. J. Med., 1989, 321:574.
Sefton, “Implantable Pumps,”CRC Crit Ref Biomed. Eng. 1987, 14:201-240.
Simonian, et al., “Oxidative Stress in Neurodegenerative Diseases,”Pharmacol. Toxicol., 1996, 36:83-106.
Smolen et al., “Controlled Drug Bioavailability,” Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984).
Sutherland et al., “Propofol and Seizures,”Anaesth. Intensive Care, 1994, 22, 733-737.
Tomioka, et al.,
Gallop Mark A.
Sasikumar Vivek
Xu Feng
Dorsey & Whitney LLP
Solola Taofiq A
XenoPort, Inc.
LandOfFree
Amino acid derived prodrugs of propofol, compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino acid derived prodrugs of propofol, compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino acid derived prodrugs of propofol, compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070781